Drugs and FDA

Merck and Daiichi withdraw lung cancer drug filing after FDA pushback

Merck and Daiichi withdrew their accelerated approval application for I-DXd after the FDA said the data were insufficient.

Reported by 3 outlets Tuesday, September 29, 2026

Cancer cells under a fluorescence microscope
Photo: CC0

Merck and Daiichi Sankyo voluntarily withdrew their application for accelerated approval of I-DXd in extensive-stage small cell lung cancer after the FDA said the data did not meet the requirements for approval.

The application was based on the phase 2 IDeate-Lung01 study, which enrolled 187 participants with extensive-stage small cell lung cancer who had previously received at least one line of platinum-based chemotherapy. The filing sought approval for patients whose cancer progressed on or after platinum-based chemotherapy.

Merck said enrollment in the phase 3 IDeate-Lung02 trial is nearing completion, and the partners may return to the FDA with an expanded dataset. I-DXd is also being tested in phase 3 trials in prostate cancer and esophageal squamous cell carcinoma.

Reporting on this story

More top stories

This Week in Medicine

The week in medicine, in five minutes

The most important medical news of the week, summarized for you and easy to read. Every Sunday, free.

Free. No spam. Unsubscribe anytime.